What is the current valuation of the Dementia Treatment Market?

As of 2024, the Dementia Treatment Market was valued at 13.04 USD Billion. Read More

What is the projected market size for the Dementia Treatment Market in 2035?

The market is projected to reach 19.41 USD Billion by 2035. Read More

What is the expected CAGR for the Dementia Treatment Market from 2025 to 2035?

The expected CAGR for the Dementia Treatment Market during the forecast period 2025 - 2035 is 3.68%. Read More

Which companies are the key players in the Dementia Treatment Market?

Key players include Eli Lilly and Company, Biogen Inc., AstraZeneca PLC, Novartis AG, Roche Holding AG, Johnson & Johnson, Pfizer Inc., Merck & Co., Inc., and Amgen Inc. Read More

What are the main types of dementia treatments available in the market?

The main types of dementia treatments include Antipsychotics, Cholinesterase Inhibitors, Memantine, and other medications. Read More

How did the market segment for Cholinesterase Inhibitors perform in 2024?

In 2024, the market segment for Cholinesterase Inhibitors was valued at 4.0 USD Billion and is expected to grow to 5.5 USD Billion. Read More

What is the market valuation for Mild Dementia treatments in 2024?

The market valuation for Mild Dementia treatments was 3.91 USD Billion in 2024, projected to increase to 5.56 USD Billion. Read More

What are the projected revenues for Injectable dementia treatments by 2035?

By 2035, the projected revenues for Injectable dementia treatments are expected to reach 7.91 USD Billion. Read More

How does the market for Severe Dementia treatments compare to Moderate Dementia treatments?

In 2024, the market for Severe Dementia treatments was valued at 3.91 USD Billion, while Moderate Dementia treatments were valued at 5.22 USD Billion. Read More

What route of administration is expected to dominate the Dementia Treatment Market?

The Oral route of administration is expected to dominate, with a projected market size of 7.0 USD Billion by 2035. Read More

Dementia Treatment Market

ID: MRFR/HC/24613-HCR

100 Pages

Satyendra Maurya

Last Updated: May 15, 2026

Dementia Treatment Market Research Report: Size, Share, Trend Analysis By Treatment Type (Antipsychotics, Cholinesterase Inhibitors, Memantine, Other (e.g., Monoamine oxidase B inhibitors, N-methyl-D-aspartate receptor antagonists), By Stage of Dementia (Mild Dementia, Moderate Dementia, Severe Dementia), By Route of Administration (Oral, Transdermal, Injectable) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035

Summary Table of Contents Segmentation Methodology Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Healthcare, BY Type (USD Billion)
  1. 4.1.1 Antipsychotics
  2. 4.1.2 Cholinesterase Inhibitors
  3. 4.1.3 Memantine
  4. 4.1.4 Other (e.g., Monoamine oxidase B inhibitors, N-methyl-D-aspartate receptor antagonists)
2. 4.2 Healthcare, BY Stage of Dementia (USD Billion)
  1. 4.2.1 Mild Dementia
  2. 4.2.2 Moderate Dementia
  3. 4.2.3 Severe Dementia
3. 4.3 Healthcare, BY Route of Administration (USD Billion)
  1. 4.3.1 Oral
  2. 4.3.2 Transdermal
  3. 4.3.3 Injectable
4. 4.4 Healthcare, BY Region (USD Billion)
  1. 4.4.1 North America
    1. 4.4.1.1 US
    2. 4.4.1.2 Canada
  2. 4.4.2 Europe
    1. 4.4.2.1 Germany
    2. 4.4.2.2 UK
    3. 4.4.2.3 France
    4. 4.4.2.4 Russia
    5. 4.4.2.5 Italy
    6. 4.4.2.6 Spain
    7. 4.4.2.7 Rest of Europe
  3. 4.4.3 APAC
    1. 4.4.3.1 China
    2. 4.4.3.2 India
    3. 4.4.3.3 Japan
    4. 4.4.3.4 South Korea
    5. 4.4.3.5 Malaysia
    6. 4.4.3.6 Thailand
    7. 4.4.3.7 Indonesia
    8. 4.4.3.8 Rest of APAC
  4. 4.4.4 South America
    1. 4.4.4.1 Brazil
    2. 4.4.4.2 Mexico
    3. 4.4.4.3 Argentina
    4. 4.4.4.4 Rest of South America
  5. 4.4.5 MEA
    1. 4.4.5.1 GCC Countries
    2. 4.4.5.2 South Africa
    3. 4.4.5.3 Rest of MEA
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Healthcare
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Eli Lilly and Company (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Biogen Inc. (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 AstraZeneca PLC (GB)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Novartis AG (CH)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Roche Holding AG (CH)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Johnson & Johnson (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Pfizer Inc. (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Merck & Co., Inc. (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Amgen Inc. (US)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 NORTH AMERICA MARKET ANALYSIS
3. 6.3 US MARKET ANALYSIS BY TYPE
4. 6.4 US MARKET ANALYSIS BY STAGE OF DEMENTIA
5. 6.5 US MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6. 6.6 CANADA MARKET ANALYSIS BY TYPE
7. 6.7 CANADA MARKET ANALYSIS BY STAGE OF DEMENTIA
8. 6.8 CANADA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
9. 6.9 EUROPE MARKET ANALYSIS
10. 6.10 GERMANY MARKET ANALYSIS BY TYPE
11. 6.11 GERMANY MARKET ANALYSIS BY STAGE OF DEMENTIA
12. 6.12 GERMANY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
13. 6.13 UK MARKET ANALYSIS BY TYPE
14. 6.14 UK MARKET ANALYSIS BY STAGE OF DEMENTIA
15. 6.15 UK MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
16. 6.16 FRANCE MARKET ANALYSIS BY TYPE
17. 6.17 FRANCE MARKET ANALYSIS BY STAGE OF DEMENTIA
18. 6.18 FRANCE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
19. 6.19 RUSSIA MARKET ANALYSIS BY TYPE
20. 6.20 RUSSIA MARKET ANALYSIS BY STAGE OF DEMENTIA
21. 6.21 RUSSIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
22. 6.22 ITALY MARKET ANALYSIS BY TYPE
23. 6.23 ITALY MARKET ANALYSIS BY STAGE OF DEMENTIA
24. 6.24 ITALY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
25. 6.25 SPAIN MARKET ANALYSIS BY TYPE
26. 6.26 SPAIN MARKET ANALYSIS BY STAGE OF DEMENTIA
27. 6.27 SPAIN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
28. 6.28 REST OF EUROPE MARKET ANALYSIS BY TYPE
29. 6.29 REST OF EUROPE MARKET ANALYSIS BY STAGE OF DEMENTIA
30. 6.30 REST OF EUROPE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
31. 6.31 APAC MARKET ANALYSIS
32. 6.32 CHINA MARKET ANALYSIS BY TYPE
33. 6.33 CHINA MARKET ANALYSIS BY STAGE OF DEMENTIA
34. 6.34 CHINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
35. 6.35 INDIA MARKET ANALYSIS BY TYPE
36. 6.36 INDIA MARKET ANALYSIS BY STAGE OF DEMENTIA
37. 6.37 INDIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
38. 6.38 JAPAN MARKET ANALYSIS BY TYPE
39. 6.39 JAPAN MARKET ANALYSIS BY STAGE OF DEMENTIA
40. 6.40 JAPAN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
41. 6.41 SOUTH KOREA MARKET ANALYSIS BY TYPE
42. 6.42 SOUTH KOREA MARKET ANALYSIS BY STAGE OF DEMENTIA
43. 6.43 SOUTH KOREA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
44. 6.44 MALAYSIA MARKET ANALYSIS BY TYPE
45. 6.45 MALAYSIA MARKET ANALYSIS BY STAGE OF DEMENTIA
46. 6.46 MALAYSIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
47. 6.47 THAILAND MARKET ANALYSIS BY TYPE
48. 6.48 THAILAND MARKET ANALYSIS BY STAGE OF DEMENTIA
49. 6.49 THAILAND MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
50. 6.50 INDONESIA MARKET ANALYSIS BY TYPE
51. 6.51 INDONESIA MARKET ANALYSIS BY STAGE OF DEMENTIA
52. 6.52 INDONESIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
53. 6.53 REST OF APAC MARKET ANALYSIS BY TYPE
54. 6.54 REST OF APAC MARKET ANALYSIS BY STAGE OF DEMENTIA
55. 6.55 REST OF APAC MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
56. 6.56 SOUTH AMERICA MARKET ANALYSIS
57. 6.57 BRAZIL MARKET ANALYSIS BY TYPE
58. 6.58 BRAZIL MARKET ANALYSIS BY STAGE OF DEMENTIA
59. 6.59 BRAZIL MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
60. 6.60 MEXICO MARKET ANALYSIS BY TYPE
61. 6.61 MEXICO MARKET ANALYSIS BY STAGE OF DEMENTIA
62. 6.62 MEXICO MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
63. 6.63 ARGENTINA MARKET ANALYSIS BY TYPE
64. 6.64 ARGENTINA MARKET ANALYSIS BY STAGE OF DEMENTIA
65. 6.65 ARGENTINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
66. 6.66 REST OF SOUTH AMERICA MARKET ANALYSIS BY TYPE
67. 6.67 REST OF SOUTH AMERICA MARKET ANALYSIS BY STAGE OF DEMENTIA
68. 6.68 REST OF SOUTH AMERICA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
69. 6.69 MEA MARKET ANALYSIS
70. 6.70 GCC COUNTRIES MARKET ANALYSIS BY TYPE
71. 6.71 GCC COUNTRIES MARKET ANALYSIS BY STAGE OF DEMENTIA
72. 6.72 GCC COUNTRIES MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
73. 6.73 SOUTH AFRICA MARKET ANALYSIS BY TYPE
74. 6.74 SOUTH AFRICA MARKET ANALYSIS BY STAGE OF DEMENTIA
75. 6.75 SOUTH AFRICA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
76. 6.76 REST OF MEA MARKET ANALYSIS BY TYPE
77. 6.77 REST OF MEA MARKET ANALYSIS BY STAGE OF DEMENTIA
78. 6.78 REST OF MEA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
79. 6.79 KEY BUYING CRITERIA OF HEALTHCARE
80. 6.80 RESEARCH PROCESS OF MRFR
81. 6.81 DRO ANALYSIS OF HEALTHCARE
82. 6.82 DRIVERS IMPACT ANALYSIS: HEALTHCARE
83. 6.83 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
84. 6.84 SUPPLY / VALUE CHAIN: HEALTHCARE
85. 6.85 HEALTHCARE, BY TYPE, 2024 (% SHARE)
86. 6.86 HEALTHCARE, BY TYPE, 2024 TO 2035 (USD Billion)
87. 6.87 HEALTHCARE, BY STAGE OF DEMENTIA, 2024 (% SHARE)
88. 6.88 HEALTHCARE, BY STAGE OF DEMENTIA, 2024 TO 2035 (USD Billion)
89. 6.89 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
90. 6.90 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Billion)
91. 6.91 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 North America MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.2.2 BY STAGE OF DEMENTIA, 2025-2035 (USD Billion)
  3. 7.2.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
2. 7.3 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.3.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.3.2 BY STAGE OF DEMENTIA, 2025-2035 (USD Billion)
  3. 7.3.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
3. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
  1. 7.4.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.4.2 BY STAGE OF DEMENTIA, 2025-2035 (USD Billion)
  3. 7.4.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
4. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.5.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.5.2 BY STAGE OF DEMENTIA, 2025-2035 (USD Billion)
  3. 7.5.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
5. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
  1. 7.6.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.6.2 BY STAGE OF DEMENTIA, 2025-2035 (USD Billion)
  3. 7.6.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
6. 7.7 UK MARKET SIZE ESTIMATES; FORECAST
  1. 7.7.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.7.2 BY STAGE OF DEMENTIA, 2025-2035 (USD Billion)
  3. 7.7.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7. 7.8 France MARKET SIZE ESTIMATES; FORECAST
  1. 7.8.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.8.2 BY STAGE OF DEMENTIA, 2025-2035 (USD Billion)
  3. 7.8.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
8. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
  1. 7.9.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.9.2 BY STAGE OF DEMENTIA, 2025-2035 (USD Billion)
  3. 7.9.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
9. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
  1. 7.10.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.10.2 BY STAGE OF DEMENTIA, 2025-2035 (USD Billion)
  3. 7.10.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
10. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
  1. 7.11.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.11.2 BY STAGE OF DEMENTIA, 2025-2035 (USD Billion)
  3. 7.11.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
11. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.12.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.12.2 BY STAGE OF DEMENTIA, 2025-2035 (USD Billion)
  3. 7.12.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
12. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.13.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.13.2 BY STAGE OF DEMENTIA, 2025-2035 (USD Billion)
  3. 7.13.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
13. 7.14 China MARKET SIZE ESTIMATES; FORECAST
  1. 7.14.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.14.2 BY STAGE OF DEMENTIA, 2025-2035 (USD Billion)
  3. 7.14.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
14. 7.15 India MARKET SIZE ESTIMATES; FORECAST
  1. 7.15.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.15.2 BY STAGE OF DEMENTIA, 2025-2035 (USD Billion)
  3. 7.15.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
15. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
  1. 7.16.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.16.2 BY STAGE OF DEMENTIA, 2025-2035 (USD Billion)
  3. 7.16.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
16. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
  1. 7.17.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.17.2 BY STAGE OF DEMENTIA, 2025-2035 (USD Billion)
  3. 7.17.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
17. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
  1. 7.18.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.18.2 BY STAGE OF DEMENTIA, 2025-2035 (USD Billion)
  3. 7.18.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
18. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
  1. 7.19.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.19.2 BY STAGE OF DEMENTIA, 2025-2035 (USD Billion)
  3. 7.19.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
19. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
  1. 7.20.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.20.2 BY STAGE OF DEMENTIA, 2025-2035 (USD Billion)
  3. 7.20.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
20. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.21.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.21.2 BY STAGE OF DEMENTIA, 2025-2035 (USD Billion)
  3. 7.21.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
21. 7.22 South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.22.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.22.2 BY STAGE OF DEMENTIA, 2025-2035 (USD Billion)
  3. 7.22.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
22. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
  1. 7.23.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.23.2 BY STAGE OF DEMENTIA, 2025-2035 (USD Billion)
  3. 7.23.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
23. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
  1. 7.24.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.24.2 BY STAGE OF DEMENTIA, 2025-2035 (USD Billion)
  3. 7.24.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
24. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
  1. 7.25.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.25.2 BY STAGE OF DEMENTIA, 2025-2035 (USD Billion)
  3. 7.25.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
25. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.26.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.26.2 BY STAGE OF DEMENTIA, 2025-2035 (USD Billion)
  3. 7.26.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
26. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.27.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.27.2 BY STAGE OF DEMENTIA, 2025-2035 (USD Billion)
  3. 7.27.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
27. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
  1. 7.28.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.28.2 BY STAGE OF DEMENTIA, 2025-2035 (USD Billion)
  3. 7.28.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
28. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
  1. 7.29.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.29.2 BY STAGE OF DEMENTIA, 2025-2035 (USD Billion)
  3. 7.29.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
29. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.30.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.30.2 BY STAGE OF DEMENTIA, 2025-2035 (USD Billion)
  3. 7.30.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
30. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.31.1
1. 7.32 ACQUISITION/PARTNERSHIP
7.32.1

Certified Researchers

Customize Report

Dementia Treatment Market Segmentation

Dementia Treatment Market By Type (USD Billion, 2025-2035)

Antipsychotics
Cholinesterase Inhibitors
Memantine
Other (e.g., Monoamine oxidase B inhibitors, N-methyl-D-aspartate receptor antagonists)

Dementia Treatment Market By Stage of Dementia (USD Billion, 2025-2035)

Mild Dementia
Moderate Dementia
Severe Dementia

Dementia Treatment Market By Route of Administration (USD Billion, 2025-2035)

Oral
Transdermal
Injectable

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”